References
- Acehan, D., Jiang, X., Morgan, D. G., Heuser, J. E., Wang, X., Akey, C. W. (2002). Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 9:423–432.
- Boddapati, S. V., G. G. D’Souza, S. Erdogan, V. P. Torchilin, and V. Weissig (2008). Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett 8:2559–2563. [Epub 2008 Jul 9].
- Boddapati, S. V., Tongcharoensirikul, P., Hanson, R. N., D’Souza, G. G., Torchilin, V. P., Weissig, V. (2005). Mitochondriotropic liposomes. J Liposome Res 15(1–2):49–58.
- Dimas, K., Demetzos, C., Vaos, V., Ioannidis, P., Trangas, T. (2001). Labdane-type diterpenes downregulate the expression of c-Myc protein, but not of Bcl-2, in human leukemia T-cells undergoing apoptosis. Leuk Res 25:449–454.
- Dimas, K., Hatziantoniou, S., Tseleni, S., Khan, H., Georgopoulos, A., Alevizopoulos, K., et al. (2007). Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice. Apoptosis 12:685–694.
- Dimas, K., Kokkinopoulos, D., Demetzos, C., Vaos, B., Marselos, M., Malamas, M., et al. (1999). The effect of sclareol on growth and cell cycle progression of human leukemic cell lines. Leuk Res 23:217–234.
- Fadeel, B., Orrenius, S. (2005). Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258:479–517.
- Gabizon, A., Papahadjopoulos, D. (1988). Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 85:6949–6953.
- Hatziantoniou, S., Dimas, K., Georgopoulos, A., Sotiriadou, N., Demetzos, C. (2006). Cytotoxic and antitumor activity of liposome-incorporated sclareol against cancer cell lines and human colon cancer xenografts. Pharmacol Res 53:80–87.
- Knight, M. J., Riffkin, C. D., Ekert, P. G., Ashley, D. M., Hawkins, C. J. (2004). Caspase-8 levels affect necessity for mitochondrial amplification in death ligand-induced glioma cell apoptosis. Mol Carcinog 39:173–182.
- Larsson, N. G., Luft, R. (1999). Revolution in mitochondrial medicine. FEBS Lett 455:199–202.
- Lim, C. S. (2007). Organelle-specific targeting in drug delivery and design. Adv Drug Deliv Rev 59:697.
- Murphy, M. P., Smith, R. A. (2000). Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 41:235–250.
- Paradissis, A., Hatziantoniou, S., Georgopoulos, A., Psarra, A. M., Dimas, K., Demetzos, C. (2007). Liposomes modify the subcellular distribution of sclareol uptake by HCT-116 cancer cell lines. Biomed Pharmacother 61(2–3):120–124.
- Rahman, A. M., Yusuf, S. W., Ewer, M. S. (2007). Anthracycline-induced cardiotoxicity and the cardia-sparing effect of liposomal formulation. Int J Nanomed 2:567–538.
- Schon, E. A., DiMauro, S. (2003). Medicinal and genetic approaches to the treatment of mitochondrial disease. Curr Med Chem 10:2523–2533.
- Thornberry, N. A., Lazebnik, Y. (1998). Caspases: enemies within. Science 281:1312–136.
- Torchilin, V. P. (2006). Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng 8:343–375.
- Torchilin, V. P., Khaw, B. A., Weissig, V. (2002). Intracellular targets for DNA delivery: nuclei and mitochondria. Somat Cell Mol Genet 27(1–6):49–64.
- Walczak, H., Krammer, P. H. (2000). The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58–66.
- Weissig, V., Boddapati, S. V., Cheng, S. M., D’Souza, G. G. (2006). Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria. J Liposome Res 16:249–264.
- Weissig, V., Cheng, S. M., D’Souza, G. G. (2004). Mitochondrial pharmaceutics. Mitochondrion 3:229–244.